Get the Stockscreener App
8.92
7.08%
0.59
After Hours:
8.96
0.04
+0.45%
Zenas Biopharma Inc stock is traded at $8.92, with a volume of 77,263.
It is up +7.08% in the last 24 hours and up +5.81% over the past month.
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.
See More
Previous Close:
$8.33
Open:
$8.27
24h Volume:
77,263
Relative Volume:
0.40
Market Cap:
$355.29M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+31.56%
1M Performance:
+5.81%
6M Performance:
-58.43%
1Y Performance:
+0.00%
1-Day Range:
$8.16
$9.01
1-Week Range:
$6.84
$9.14
52-Week Range:
$5.83
$26.25
Zenas Biopharma Inc Stock (ZBIO) Company Profile
Name
Zenas Biopharma Inc
Sector
Industry
Phone
857-271-2954
Address
852 WINTER STREET, SUITE 250, WALTHAM
Compare ZBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZBIO
Zenas Biopharma Inc
|
8.92 | 355.29M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Zenas Biopharma Inc Stock (ZBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-20-25 | Initiated | Wedbush | Outperform |
| Feb-04-25 | Initiated | Wolfe Research | Outperform |
| Dec-16-24 | Initiated | H.C. Wainwright | Buy |
| Nov-05-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-08-24 | Initiated | Citigroup | Buy |
| Oct-08-24 | Initiated | Guggenheim | Buy |
| Oct-08-24 | Initiated | Jefferies | Buy |
| Oct-08-24 | Initiated | Morgan Stanley | Overweight |
View All
Zenas Biopharma Inc Stock (ZBIO) Latest News
ROSEN, THE FIRST FILING FIRM, Encourages Zenas BioPharma, - GlobeNewswire
ZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Lawsuit Filed by The Rosen Law Firm - Morningstar
ROSEN, THE FIRST FILING FIRM, Encourages Zenas BioPharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – ZBIO - TradingView
ROSEN, THE FIRST FILING FIRM, Encourages Zenas BioPharma, Inc. Investors to Secure Counsel - Bluefield Daily Telegraph
ROSEN, THE FIRST FILING FIRM, Encourages Zenas BioPharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – ZBIO - GlobeNewswire Inc.
Shareholder Alert: Robbins LLP Informs Stockholders of the Zenas BioPharma, Inc. Class Action Lawsuit - PR Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
ZBIO INVESTOR ALERT: Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – Company AnnouncementFT.com - Financial Times
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Zenas BioPharma, Inc. (ZBIO) - TradingView
INVESTOR ALERT: Cohen Milstein Calls on Zenas BioPharma - GlobeNewswire
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Zenas BioPharma Faces Investor Suit Over Post-IPO Plunge - Law360
ZBIO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma - Business Wire
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of - GlobeNewswire
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Zenas BioPharma, Inc. (ZBIO) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm - TradingView
ZBIO INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Business Wire
Reviewing Zenas Biopharma (ZBIO) and Its Peers - Defense World
ZBIO INVESTOR NEWS: ROSEN, THE FIRST FILING FIRM, - GlobeNewswire
ZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Business Wire
ZBIO INVESTOR NEWS: ROSEN, THE FIRST FILING FIRM, Encourages Zenas BioPharma, Inc. Investors to - Bluefield Daily Telegraph
ZBIO INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP - GlobeNewswire
ZBIO INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead the Zenas BioPharma Class Action Lawsuit - TradingView
ZBIO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - markets.businessinsider.com
EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Zenas BioPharma, Inc. – ZBIO - Business Wire
ZBIO Investor News: Rosen Law Firm Encourages Zenas BioPharma, Inc. Investors to Inquire About Securities Class Action InvestigationZBIO - PR Newswire
Zenas BioPharma, Inc. Announcement: If You Have Suffered - GlobeNewswire
Zenas BioPharma, Inc. Announcement: If You Have Suffered Losses in Zenas BioPharma, Inc. - Bluefield Daily Telegraph
Zenas BioPharma, Inc. Announcement: If You Have Suffered Losses in Zenas BioPharma, Inc. (NASDAQ: ZBIO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights - TradingView
Contrasting Zenas Biopharma (ZBIO) & The Competition - Defense World
Zenas BioPharma, Inc. Investor News: If You Have Suffered - GlobeNewswire
Zenas BioPharma, Inc. Investor News: If You Have Suffered Losses in Zenas BioPharma, Inc. - Bluefield Daily Telegraph
The Escalator: Rocket Pharmaceuticals, Zenas BioPharma, Angelini Ventures - Medical Marketing and Media
Critical Comparison: Zenas Biopharma (ZBIO) vs. Its Peers - Defense World
Zenas Biopharma (ZBIO) versus The Competition Head-To-Head Review - Defense World
Zenas Biopharma (ZBIO) and Its Competitors Financial Analysis - Defense World
Zenas BioPharma names Haley Laken as chief scientific officer - MSN
Zenas BioPharma names new Chief Scientific Officer By Investing.com - Investing.com South Africa
Zenas BioPharma names new Chief Scientific Officer - Investing.com Australia
Zenas: Differentiated B-Cell Targeting Drug With Q3 Of 2025 Catalyst (NASDAQ:ZBIO) - Seeking Alpha
Zenas BioPharma Appoints Haley Laken, Ph.D., as Chief Scientific Officer - The Manila Times
Zenas Biopharma (ZBIO) and Its Competitors Financial Review - Defense World
Zenas Biopharma (ZBIO) versus Its Rivals Head to Head Review - Defense World
Zenas Biopharma (ZBIO) vs. Its Peers Critical Analysis - Defense World
Zenas Biopharma (ZBIO) and The Competition Financial Comparison - Defense World
Comparing Zenas Biopharma (ZBIO) and Its Rivals - Defense World
Financial Survey: Zenas Biopharma (ZBIO) and Its Rivals - Defense World
Zenas Biopharma Inc Stock (ZBIO) Financials Data
There is no financial data for Zenas Biopharma Inc (ZBIO). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):